PL2828284T3 - Przeciwciała neutralizujące wirus jc - Google Patents

Przeciwciała neutralizujące wirus jc

Info

Publication number
PL2828284T3
PL2828284T3 PL13765090T PL13765090T PL2828284T3 PL 2828284 T3 PL2828284 T3 PL 2828284T3 PL 13765090 T PL13765090 T PL 13765090T PL 13765090 T PL13765090 T PL 13765090T PL 2828284 T3 PL2828284 T3 PL 2828284T3
Authority
PL
Poland
Prior art keywords
neutralizing antibodies
jcv neutralizing
jcv
antibodies
neutralizing
Prior art date
Application number
PL13765090T
Other languages
English (en)
Inventor
Kenneth Simon
Thomas Cameron
Deping Wang
Joseph Arndt
Mia Rushe
Justin Caravella
Eric Day
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PL2828284T3 publication Critical patent/PL2828284T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL13765090T 2012-03-20 2013-03-15 Przeciwciała neutralizujące wirus jc PL2828284T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613214P 2012-03-20 2012-03-20
PCT/US2013/031842 WO2013142299A1 (en) 2012-03-20 2013-03-15 Jcv neutralizing antibodies
EP13765090.9A EP2828284B1 (en) 2012-03-20 2013-03-15 Jcv neutralizing antibodies

Publications (1)

Publication Number Publication Date
PL2828284T3 true PL2828284T3 (pl) 2019-11-29

Family

ID=49223243

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13765090T PL2828284T3 (pl) 2012-03-20 2013-03-15 Przeciwciała neutralizujące wirus jc

Country Status (15)

Country Link
US (1) US9567392B2 (pl)
EP (2) EP2828284B1 (pl)
CA (1) CA2867902C (pl)
CY (1) CY1121856T1 (pl)
DK (1) DK2828284T3 (pl)
ES (1) ES2731757T3 (pl)
HR (1) HRP20190937T1 (pl)
HU (1) HUE044838T2 (pl)
LT (1) LT2828284T (pl)
PL (1) PL2828284T3 (pl)
PT (1) PT2828284T (pl)
RS (1) RS58910B1 (pl)
SI (1) SI2828284T1 (pl)
TR (1) TR201909801T4 (pl)
WO (1) WO2013142299A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2828284B1 (en) 2012-03-20 2019-05-08 Biogen MA Inc. Jcv neutralizing antibodies
ES2706173T3 (es) 2012-03-20 2019-03-27 Biogen Ma Inc Anticuerpos de neutralización de JCV
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
JP2022537544A (ja) * 2019-06-19 2022-08-26 アイカーン スクール オブ メディスン アット マウント シナイ Ｊｃウイルスに対するモノクローナル抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
SG170749A1 (en) 2005-12-20 2011-05-30 Sbi Biotech Co Ltd Anti-ilt7 antibody
JP2009536641A (ja) 2006-05-31 2009-10-15 ハンワ ケミカル コーポレイション Ｖｃａｍ−１特異的モノクローナル抗体
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
PT2308514E (pt) * 2007-03-23 2013-09-06 To Bbb Holding B V Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
WO2010090757A1 (en) 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
WO2010129959A1 (en) 2009-05-08 2010-11-11 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies
EP2316481A1 (en) 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
EP2828284B1 (en) 2012-03-20 2019-05-08 Biogen MA Inc. Jcv neutralizing antibodies
ES2706173T3 (es) 2012-03-20 2019-03-27 Biogen Ma Inc Anticuerpos de neutralización de JCV

Also Published As

Publication number Publication date
CY1121856T1 (el) 2020-07-31
DK2828284T3 (da) 2019-06-11
US20150050271A1 (en) 2015-02-19
TR201909801T4 (tr) 2019-07-22
EP2828284B1 (en) 2019-05-08
HUE044838T2 (hu) 2019-11-28
WO2013142299A1 (en) 2013-09-26
EP2828284A1 (en) 2015-01-28
PT2828284T (pt) 2019-06-17
HRP20190937T1 (hr) 2019-10-04
US9567392B2 (en) 2017-02-14
EP3575311A1 (en) 2019-12-04
RS58910B1 (sr) 2019-08-30
CA2867902A1 (en) 2013-09-26
LT2828284T (lt) 2019-08-26
EP2828284A4 (en) 2015-07-22
ES2731757T3 (es) 2019-11-18
SI2828284T1 (sl) 2019-10-30
CA2867902C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
IL264558A (en) Anti–il–23p19 antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2837685A4 (en) ANTI-FGFR2 ANTIBODIES
EP2826790A4 (en) GREMLIN-1 ANTIBODY
EP2828292A4 (en) JCV NEUTRALIZING ANTIBODIES
IL234883A0 (en) CDR-modified anti-siglac-15 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HUE044838T2 (hu) JCV neutralizáló antitestek
PL2935330T3 (pl) Przeciwciała przeciw notch3
GB201220242D0 (en) Antibody
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations